LKFT Lakefront Biotherapeutics NV

33.87USD30.88 EUR · AMS-1.40%Mkt Cap: 2.23B USDP/E: 2.57

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…

Institutional holders10 on file

Key Statistics

Company
Market Cap2.23B USD
Enterprise Value-225.67M USD
Revenue (TTM)1.09B USD
Gross Profit1.19B USD
Net Income (TTM)351.95M USD
Revenue/Share16.49 USD
Last Price33.87 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINBE0003818359
Valuation
P/E (Trailing)2.57
P/E (Forward)-9.18
PEG—
EV/EBITDA-0.36
EV/Revenue-0.21
P/S2.05
P/B0.62
EPS (TTM)13.16 USD
EPS (Forward)-3.69 USD
52W Range
24.4888% of range35.19
52W High35.19 USD
52W Low24.48 USD
Profitability
Gross Margin97.33%
Oper. Margin57.49%
EBITDA Margin57.43%
Profit Margin28.85%
ROE9.92%
ROA9.42%
ROIC204.87%
ROCE15.41%
Growth
Revenue Growth-81.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-282.38M USD
CapEx (TTM)15.20M USD
FCF Margin13.95%
FCF Yield6.79%
Net Debt-2.45B USD
Net Debt/EBITDA-3.93
Net Debt/FCF-16.16
Balance Sheet
Debt/Equity0.00
Current Ratio32.84
Quick Ratio32.65
Book Value/Sh54.52 USD
Cash/Share37.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.4 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.77 USD
Upside (mean)+5.6%
Target Range20.84 USD – 49.14 USD
20.84+5.6% to mean49.14
# Analysts7
Ownership
Shares Out.65.90M
Float23.02M
Insiders25.36%
Institutions43.59%
Technical
SMA 5029.91 (+13.2%)
SMA 20028.38 (+19.4%)
Beta0.01
S&P 52W Chg12.00%
Avg Vol (30d)84.56K
Avg Vol (10d)100.38K
Technical Indicators
RSI (14)63.9
MACD1.1021
MACD Signal1.0375
MACD Hist.+0.0646
BB Upper34.96 USD
BB Middle32.52 USD
BB Lower30.07 USD
BB Width15.05%
ATR (14)1.040 USD
Vol Ratio (20d)1.06x

About Lakefront Biotherapeutics (AMS: LKFT)

›

Lakefront Biotherapeutics (AMS: LKFT) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 196 employees.

The shares were at 30.88 EUR on 19 November 2026, up 16.6% over 52 weeks. Its 52-week range is 22.32 EUR to 32.08 EUR: the price is 3.7% below the high and 38.4% above the low.

At a market capitalisation of 2.03B EUR, it trades at 2.6 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 92% for LKFT.

Lakefront Biotherapeutics reports return on equity of 9.9%, an operating margin of 57.5% and revenue down 81.5% year over year.

It holds more cash than debt, a net cash position of 2.23B EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 32.61 EUR is 5.6% above the current price. The next earnings report is expected on 24 February 2027.